SLOVENSKI STANDARD
oSIST prEN ISO 18562-4:2023

01-januar-2023

Ovrednotenje biokompatibilnosti vdihanega plina za uporabo v zdravstvu - 4. del: Preskusi izlužnin v kondenzatih (ISO/DIS 18562-4:2022)

Biocompatibility evaluation of breathing gas pathways in healthcare applications - Part 4: Tests for leachables in condensate (ISO/DIS 18562-4:2022)

Beurteilung der Biokompatibilität der Atemgaswege bei medizinischen Anwendungen - Teil 4: Prüfungen für herauslösbare Substanzen in Kondensaten (ISO/DIS 18562-4:2022)

Évaluation de la biocompatibilité des chemins de gaz respiratoires dans les applications de soins de santé - Partie 4: Essais concernant les substances relargables dans le condensat (ISO/DIS 18562-4:2022)

Ta slovenski standard je istoveten z: **prEN ISO 18562-4**

ICS:

11.040.10	Anestezijska, respiratorna in reanimacijska oprema	Anaesthetic, respiratory and reanimation equipment

oSIST prEN ISO 18562-4:2023 **en,fr,de**

DRAFT INTERNATIONAL STANDARD
ISO/DIS 18562-4

ISO/TC **121**/SC **3** Secretariat: **ANSI**

Voting begins on:
2022-11-03

Voting terminates on:
2023-01-26

Biocompatibility evaluation of breathing gas pathways in healthcare applications —

Part 4:
Tests for leachables in condensate

Évaluation de la biocompatibilité des chemins de gaz respiratoires dans les applications de soins de santé —

Partie 4: Essais concernant les substances relargables dans le condensat

ICS: 11.040.10

This document is circulated as received from the committee secretariat.

ISO/CEN PARALLEL PROCESSING

Reference number
ISO/DIS 18562-4:2022(E)

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword ..... **iv**

Introduction ..... **v**

1 Scope **1**

2 Normative references **1**

3 Terms and definitions **2**

4 General principles **3**
4.1 *Type tests* 3
4.2 General 3

5 *Leachables* in condensate **3**
5.1 Identifying applicable *gas pathway* surfaces 3
5.2 Determining if testing is required 3
5.3 Test methods 4
5.3.1 General 4
5.3.2 Sample collection 5
5.3.3 Chemical characterization of *leachables* in condensate 6
5.3.4 Calculation of tolerable exposure 7
5.3.5 Calculation of *exposure dose* estimate 7
5.3.6 *Risk assessment* 7
5.3.7 Biological evaluation according to ISO 10993 standards 8

6 Reporting **9**

Annex A (informative) **Rationale and guidance** **10**

Annex B (informative) **Reference to the IMDRF *essential principles* and labelling guidances** **12**

Annex C (informative) **Reference to the *essential principles*** **13**

Annex ZA (informative) **Relationship between this European standard and the General Safety and Performance Requirements of Regulation (EU) 2017/745 aimed to be covered** **14**

Bibliography **17**

Terminology — Alphabetized index of defined terms **19**

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 121, *Anaesthetic and respiratory equipment*, Subcommittee SC 3, *Respiratory devices and related equipment used for patient care* in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 215, *Respiratory and anaesthetic equipment*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 18562-4:2017), which has been technically revised. The main changes compared to the previous edition are as follows:

— reformatted according to most recent Central Secretariat editing rules;

— added informative mapping annexes to relevant regulatory requirements;

— clarified terms and definitions used in the document;

— clarified the stepwise test procedure;

— required determination of volume of condensate that can reach the *patient*; and

— required calculating resulting *exposure dose*.

A list of all parts in the ISO 18562 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document is intended to protect *patients* connected to *medical devices* from harmful amounts of substances that might be dissolved in water that has condensed in the *gas pathways* of those *medical devices*. This document represents the application of the best-known science by addressing the *risks* from potentially hazardous substances in the condensate being conveyed to the *patient* by the *gas pathway*. The condensate itself will be distilled water, having condensed from the vapour phase. But substances from within the *medical device* could leach into the liquid water (condensate) present in the breathing system.

This document is intended to cover the biological evaluation of *gas pathways* of *medical devices* within a *risk management process*, as part of the overall *medical device* evaluation and development. This approach combines the review and evaluation of existing data from all sources with, where necessary, the selection and application of additional tests.

In general, the ISO 10993 series is intended to cover the biological evaluation of *medical devices*. However, the ISO 10993 series does not appropriately address the biological evaluation of the *gas pathways* of *medical devices*.

It is not within the scope of this document to address contamination arising from the source of the breathing gases entering such *medical devices*, but rather only address the potential contamination generated from within the *medical device* itself. This contamination might be from the original manufacturing *process* or generated by the *medical device* itself during use.

This document is concerned with substances that could be conveyed to the *patient* by liquid condensate forming in the *medical device* and then subsequently reaching the lungs of the *patient*. Potentially harmful substances that could be found in condensate include organic compounds and elements (such as metals). Condensate management is part of most healthcare institution protocols, with the primary aim of preventing the condensate reaching the *patient* in the first place. The absolute volume of liquid reaching a *patient* by this route should therefore be low, but it might happen. This document outlines tests for substances contained in the liquid.

The methods to determine the acceptable levels of contamination are contained in ISO 18562-1.

In this document, the following print types are used:

— requirements and definitions: roman type;

— informative material appearing outside of tables, such as notes, examples and references: in smaller type. Normative text of tables is also in a smaller type;

— *terms defined in Clause 3 of this document or as noted and test specifications: italic type*;

This document has been prepared in consideration of:

— the *Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices,* IMDRF/GRRP WG/N47:2018[17] as indicated in Annex B;

— the *Labelling Principles for Medical Devices and IVD Medical Devices,* IMDRF/GRRP WG/N52:2019[18] as indicated in Annex B;

— the *essential principles of safety and performance* of a *medical device* according to ISO 16142-1:2016[15] as indicated in Annex C; and

— the general safety and performance requirements of a *medical device* according to regulation (EU) 2017/745[19].

In this document, the conjunctive “or” is used as an “inclusive or” so a statement is true if any combination of the conditions is true.

For the purposes of this document, the auxiliary verb:

— “shall” indicates a requirement;

— “should” indicates a recommendation;

— “may” indicates a permission;

— "can" is used to describe a possibility or capability, and

— "must" indicates an external constraint.

Requirements in this document have been decomposed so that each requirement is uniquely delineated. This is done to support automated requirements tracking.

Biocompatibility evaluation of breathing gas pathways in healthcare applications —

Part 4: Tests for leachables in condensate

1 Scope

This document specifies tests for substances leached by liquid water condensing in *gas pathways* of a *medical device*, its parts or *accessories,* which are intended to provide respiratory care or supply substances via the respiratory tract to a *patient* in all environments. The chemical characterization methods described in this document apply to chemical substances that could leach from the *medical device*, its parts or *accessories* into the condensate. This document establishes verifiable acceptance criteria for these tests. The identity and quantity of each chemical released is intended for toxicological *risk assessment* as described in ISO 18562-1:—[1)].

This document addresses potential contamination of the gas stream arising from the *gas pathways*, which is delivered to the *patient*.

This document applies over the *expected lifetime* of the *medical device* in *normal use* and takes into account the effects of any intended *processing*.

This document does not address biological evaluation of the surfaces of *gas pathways* that have direct contact with the *patient*. The requirements for direct contact surfaces are found in the ISO 10993 series.

Medical devices, parts or *accessories* containing *gas pathways* that are addressed by this document include, but are not limited to, ventilators, anaesthesia workstations (including gas mixers), breathing systems, oxygen conserving devices, oxygen concentrators, nebulizers, low-pressure hose assemblies, humidifiers, heat and moisture exchangers, respiratory gas monitors, respiration monitors, masks, mouth pieces, resuscitators, breathing tubes, breathing systems filters, Y-pieces and any breathing *accessories* intended to be used with such devices. The enclosed chamber of an incubator, including the mattress, and the inner surface of an oxygen hood are considered to be *gas pathways* and are also addressed by this document.

This document does not address contamination already present in the gas supplied from the gas sources while *medical devices* are in *normal use*.

EXAMPLE Contamination arriving at the *medical device* from gas sources such as medical gas pipeline systems (including the non-return valves in the pipeline outlets), outlets of pressure regulators connected or integral to a medical gas cylinder, or room air taken into the *medical device*.

This document does not address contact with drugs or anaesthetic agents. If a *medical device* or *accessory* is intended to be used with anaesthetic agents or drugs, then additional testing can be required.

This document is intended to be read in conjunction with ISO 18562-1:—.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

1) Under preparation. Stage at the time of publication: ISO/DIS 18562-1:2022.

ISO 10993-1:2018, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-5:2009, *Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity*

ISO 10993-10:2021, *Biological evaluation of medical devices — Part 10: Tests for skin sensitization*

ISO 10993-12:2021, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 10993-18:2020+AMD1:2022, *Biological evaluation of medical devices — Part 18: Chemical characterization of materials*

ISO 10993-23:2020, *Biological evaluation of medical devices — Part 23: Tests for irritation*

ISO 18562-1:—, *Biocompatibility evaluation of breathing gas pathways in healthcare applications — Part 1: Evaluation and testing within a risk management process*

ICH Q3D(R1):2016[2)], *Guideline for elemental impurities*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 18562-1:— and the following apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

— IEC Electropedia: available at https://www.electropedia.org/

— ISO Online browsing platform: available at https://www.iso.org/obp

NOTE For convenience, an alphabetized index of all defined terms and their sources used in this document are given at the end of the document.

3.1
exaggerated extraction
extraction that is intended to result in a greater amount of a chemical constituent being released as compared to the amount generated under the simulated conditions of use

Note 1 to entry: It is important to ensure that the *exaggerated extraction* does not result in a chemical change of the material.

[SOURCE: ISO 10993-12:2021, 3.3]

3.2
extractable
substance that is released from a *medical device* or material of construction when the *medical device* or material is extracted using laboratory extraction conditions and vehicles

[SOURCE: ISO 10993-18:2020+AMD1:2022, 3.16]

2) Available at: (viewed 2021 03-12)
https://admin.ich.org/sites/default/files/inline-files/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf

4 General principles

4.1 *Type tests*

The tests described in this document are *type tests*. *Type tests* are performed on the final *medical device*, a component of the *medical device*, portions of the final finished *medical device* or a representative sample of the *medical device*, part or *accessory* being evaluated.

a) If representative samples are used, (i.e. manufactured and processed by equivalent methods), consideration shall be made regarding whether or not the differences between the representative sample and the final *medical device* or component could affect the results of the test.

b) Testing of representative samples (manufactured and processed by equivalent methods) instead of the final *medical device* shall:

   1) be supported by a description of any differences between the representative sample and the final *medical device*; and

   2) include a detailed rationale for why each difference is not expected to impact the *biocompatibility* of the final *medical device*.

      NOTE Some *authorities having jurisdiction* evaluate these differences and rationales.

4.2 General

All *gas pathways* from which the *patient* inspires gas shall be evaluated using the principles detailed in ISO 18562-1:—.

5 *Leachables* in condensate

5.1 Identifying applicable *gas pathway* surfaces

a) A *medical device*, its parts or *accessories* shall not add *leachables* to the condensate at levels that create an unacceptable *risk* to the *patient.*

b) All *gas pathways* from which the *patient* inspires gas in *normal use* and *normal condition* shall be evaluated for *leachables* in condensate, where

   — gas in the *gas pathway* can reach 100 % saturation with water at some point in the *gas pathway*,

   — condensate can form on the *gas pathway* surfaces, and

   — liquid condensate can reach the *patient*.

      NOTE 1 Condensate, which in itself is water, can form in *gas pathways* and can take the form of liquid drops or a film of water on the *gas pathway* walls. This liquid water can extract substances from the materials of the walls that would not be extracted by the breathing gas alone. If this liquid condensate can reach the *patient,* it could potentially convey harmful substances to the *patient*.

   1) Reasonably foreseeable *use errors* that can affect condensate reaching the *patient* should also be considered one *use error* at a time.

      NOTE 2 Reasonably foreseeable *use errors* can include incorrect equipment set up.

5.2 Determining if testing is required

a) The evaluation should use the *risk management process* to assess if testing is required.

b) Sections of the *gas pathway* from which the *patient* cannot be exposed to condensate need not be tested.